Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979096

SCHEMBL1979096

SCHEMBL1979096

CC[C@@]1(C)NC(=O)N(c2ccc(Oc3ccc(C#N)cc3C3CC3)nc2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 7/20 0.38
▸ HSD11B2 P80365 3/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ PTH1R Q03431 2/20 0.34
▸ ELANE P08246 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.33
▸ PDE5A O76074 2/20 0.33
▸ AR P10275 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ TRPV4 Q9HBA0 1/20 0.32
▸ IP6K1 Q92551 1/20 0.32
▸ EZH2 Q15910 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939616 1.00 HSD11B1 (0.38) HSD11B1HSD11B2PTGDR2PTH1RELANE
SCHEMBL30939574 0.89 AR (0.41) HSD11B1HSD11B2PTGDR2PTH1RCYP11B2
SCHEMBL1979977 0.89 AR (0.41) HSD11B1HSD11B2PTGDR2PTH1RCYP11B2
SCHEMBL1979370 0.84 ELANE (0.35) HSD11B1HSD11B2ELANEARTRPV4
SCHEMBL30939539 0.84 ELANE (0.35) HSD11B1HSD11B2ELANEARTRPV4
SCHEMBL30939605 0.83 SLC22A12 (0.37) HSD11B1HSD11B2ARHRH3
SCHEMBL1984305 0.83 SLC22A12 (0.37) HSD11B1HSD11B2ARHRH3
SCHEMBL18952976 0.83 HSD11B1 (0.34) HSD11B1HSD11B2ELANEARTRPV4
SCHEMBL22026251 0.82 GRIN1 (0.34) HSD11B1HSD11B2PTH1RELANECYP11B2
SCHEMBL18952943 0.82 PTGDR2 (0.37) HSD11B1HSD11B2PTGDR2PTH1RCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 — — US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 — — US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 — — US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 — — US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 — — EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 — — US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 — — US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 — — CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 — — CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSD11B1 1850/4885HSD11B2 1636/4885PTGDR2 2252/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 HSD11B1 3432/4885HSD11B2 3739/4885PTGDR2 697/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSD11B1 1875/4885HSD11B2 1758/4885PTGDR2 1643/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 HSD11B1 3432/4885HSD11B2 3739/4885PTGDR2 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.